=> fil reg
FILE 'REGISTRY' ENTERED AT 16:25:56 ON 10 JUL 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 9 JUL 2001 HIGHEST RN 345196-14-7
DICTIONARY FILE UPDATES: 9 JUL 2001 HIGHEST RN 345196-14-7

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> d sta que l8
L4 STR



VAR G1=X/NO2/N/C/CY
NODE ATTRIBUTES:
NSPEC IS RC AT 4
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
L5 29663 SEA FILE=REGISTRY ABB=ON PLU=ON NCSC2/ES
L7 1667 SEA FILE=REGISTRY SUB=L5 SSS FUL L4
L8 1250 SEA FILE=REGISTRY ABB=ON PLU=ON L7 AND (16.299.11 OR 16.299.12)/RID

=> d his l8-

(FILE 'REGISTRY' ENTERED AT 16:11:49 ON 10 JUL 2001)
SAV GERSTL807 A L7
L8 1250 S L7 AND (16.299.11 OR 16.299.12)/RID
L9 417 S L7 NOT L8

FILE 'HCAPLUS' ENTERED AT 16:13:43 ON 10 JUL 2001
L10 139 S L8
L11 26 S L8 (L) THU/FL
L12 47 S L8 (L) BAC/FL
L13 57 S L8 AND (1 OR (3)/SC,SX
L14 74 S L11-L13
L15 13[illegible] S L10 AND (PY<=1998 OR PRY<=1998 OR AY<=1998)
L16 [illegible] S L15 AND L14
L17 38 S L15 AND (?NEOPLAS? OR ?TUMOR? OR ?TUMOUR? OR ?CANCER? OR ?CAR
L18 4 S L15 AND (?PROLIFERAT? OR ?CYTOTOX?)
L19 [illegible] S L17,L18
L20 2[illegible] S L19 NOT (1 OR 63)/SC,SX
L21 3 S L20 NOT 4/SC
L22 2 S L21 NOT 17/SC
L23 15 S L19 NOT L20

```
L24          11 S L23 NOT 4/SC
L25           6 S L14 AND (RAF OF LEWIS OR CYCLIN OR INOSINE OR ANTITUMOR)/TI
L26           8 S L12,L25
L27          47 S L16 NOT L17
L28          45 S L27 NOT 4/SC

     FILE 'REGISTRY' ENTERED AT 16:25:56 ON 10 JUL 2001

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 16:26:10 ON 10 JUL 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 10 Jul 2001  VOL 135 ISS 3
FILE LAST UPDATED: 9 Jul 2001  (20010709/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 This file supports REGISTRY for direct browsing and searching of
 all substance data from the REGISTRY file.  Enter HELP FIRST for
 more information.

HCAplus now provides online access to patents and literature covered
in CA from 1947 to the present.  On April 22, 2001, bibliographic
information and abstracts were added for over 2.2 million references
published in CA from 1947 to 1966.


=> d 126 bib abs hitrn fhitstr tot

L26  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2001 ACS
AN   2001:111513  HCAPLUS
DN   134:163040
TI   Preparation of heteroaryl aryl ureas as raf kinase inhibitors
IN   Wood, Jill E.; Wild, Hanno; Rogers, Daniel H.; Lyons, John; Katz, Michael;
     Caringal, Yolanda; Dally, Robert; Lee, Wendy; Smith, Roger A.; Blum, Cheri
PA   Onyx Pharmaceuticals, USA; Bayer Corporation
SO   U.S., 30 pp.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.   DATE
     ---------------    ----  --------       ---------------   --------
PI   US 6187799         B1    20010213       US 1998-83399     19980522 <--
     US 2001006975      A1    20010705       US 2001-755060    20010108 <--
PRAI US 1997-126420     P     19970523  <--
     US 1998-83399      A3    19980522  <--
GI
```



I

AB The title heteroaryl aryl ureas, useful in treating **tumors** mediated by raf kinase (no data), were prepd. E.g., a multi-step synthesis of the urea I was given. The title compds. such as I are effective at 0.01-200 mg/kg/day.

IT **216589-90-1P**
PL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryl aryl ureas as raf kinase inhibitors)

IT **216589-90-1P**
PL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryl aryl ureas as raf kinase inhibitors)

RN 216589-90-1 HCAPLUS
CN 2-Thiophenecarboxylic acid, 5-(1,1-dimethylethyl)-3-[[[(5-methyl-2-thiazolyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 36
RE
(1) Acker; US 4437878 1984 HCAPLUS
(2) Aldrich; US 4009847 1977 HCAPLUS
(3) Anon; JP 54-32468 1979 HCAPLUS
(4) Anon; DE 3305866 1984 HCAPLUS
(5) Anon; WO 9324458 1993 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2001 ACS
AN 2000:314688 HCAPLUS
DN 132:334455
TI 2-Ureidothiazole derivatives, process for their preparation, and their use as **antitumor** agents
IN Pevarello, Paolo; Amici, Raffaella; Traquandi, Gabriella; Villa, Manuela; Vulpetti, Anna; Isacchi, Antonella
PA Pharmacia & Upjohn S.p.A., Italy
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2000026203 A1 20000511 WO 1999-EP8307 19991027 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI GB 1998-23873 A 19981030 <--
OS MARPAT 132:334455
GI



AB The title 2-ureido-1,3-thiazole derivs. I and their pharmaceutically acceptable salts are disclosed [wherein R = halo, nitro, (un)substituted amino, C1-6 alkyl, C3-6 cycloalkyl, aryl, or arylalkyl; R1 = (un)substituted C1-6 alkyl, 3- to 6-membered carbocycle or 5- to 7-membered heterocycle, aryl, arylcarbonyl, or arylalkyl; R2 = H, straight or branched C1-4 alkyl, C2-4 alkenyl, or alkynyl; or NR1R2 = (un)substituted, optionally benzo-condensed or bridged 5- to 7-membered heterocycle, or 9- to 11-membered spiro-heterocycle]. The compds. are active as cdk/cyclin inhibitors, and are useful for treating cell **proliferative** disorders assocd. with an altered cell dependent kinase activity. The **proliferative** disorders include **cancer** and a wide variety of other conditions, such as Alzheimer's disease, viral infections, autoimmune diseases, and neurodegenerative disorders. Over 230 invention compds. are claimed and/or prepd. in examples. For instance, reaction of Ph isocyanate with 2-amino-5-bromo-1,3-thiazole hydrobromide in the presence of Et3N gave title compd. I [R = Br, R1 = Ph, R2 = H]. The similarly prepd. title compd. I [R = iso-Pr, R1 = 3,5-dimethylphenyl, R2 = H] inhibited cdk2/cyclin A complex in vitro with an IC50 of 0.56 .mu.M.

IT **267431-26-5**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-nitrophenyl)urea
RL: RCT (Reactant)
(starting material; prepn. of ureidothiazole derivs. as **antitumor** agents)

IT **267429-35-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-nitrophenyl)urea **267429-43-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-nitrophenyl)urea **267429-47-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-aminophenyl)urea **267431-00-5P**, N-(3-Iodophenyl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of ureidothiazole derivs. as **antitumor** agents)

IT **14954-34-8P**, N-(5-Methyl-1,3-thiazol-2-yl)-N'-phenylurea **202056-91-5P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(4-chlorophenyl)urea **267428-92-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-phenylurea **267428-93-3P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-phenylurea **267428-94-4P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-phenylurea **267428-95-5P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-phenylurea **267428-96-6P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(4-sulfamoylphenyl)urea **267428-97-7P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-sulfamoylphenyl)urea **267428-98-8P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(4-sulfamoylphenyl)urea **267428-99-9P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(4-

sulfamoylphenyl)urea **267429-00-5P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-methoxyphenyl)urea **267429-01-6P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(3-methoxyphenyl)urea **267429-02-7P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(3-methoxyphenyl)urea **267429-03-8P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(3-methoxyphenyl)urea **267429-04-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-chlorophenyl)urea **267429-05-0P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(4-chlorophenyl)urea **267429-06-1P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(4-chlorophenyl)urea **267429-07-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-chlorophenyl)urea **267429-08-3P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(3-chlorophenyl)urea **267429-09-4P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(3-chlorophenyl)urea **267429-10-7P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(3-chlorophenyl)urea **267429-11-8P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-chlorophenyl)urea **267429-12-9P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(2-chlorophenyl)urea **267429-13-0P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(2-chlorophenyl)urea **267429-14-1P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(2-chlorophenyl)urea **267429-15-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-methoxyphenyl)urea **267429-16-3P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(4-methoxyphenyl)urea **267429-17-4P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(4-methoxyphenyl)urea **267429-18-5P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(4-methoxyphenyl)urea **267429-19-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-hydroxyphenyl)urea **267429-20-9P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(4-hydroxyphenyl)urea **267429-21-0P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(4-hydroxyphenyl)urea **267429-22-1P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(4-hydroxyphenyl)urea **267429-23-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-hydroxyphenyl)urea **267429-24-3P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(3-hydroxyphenyl)urea **267429-25-4P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(3-hydroxyphenyl)urea **267429-26-5P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(3-hydroxyphenyl)urea **267429-27-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-methoxyphenyl)urea **267429-28-7P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(2-methoxyphenyl)urea **267429-29-8P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(2-methoxyphenyl)urea **267429-30-1P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(2-methoxyphenyl)urea **267429-31-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-hydroxyphenyl)urea **267429-32-3P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(2-hydroxyphenyl)urea **267429-33-4P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(2-hydroxyphenyl)urea **267429-34-5P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(2-hydroxyphenyl)urea **267429-36-7P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(4-nitrophenyl)urea **267429-37-8P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(4-nitrophenyl)urea **267429-38-9P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(4-nitrophenyl)urea **267429-39-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-aminophenyl)urea **267429-40-3P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(4-aminophenyl)urea **267429-41-4P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(4-aminophenyl)urea **267429-42-5P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(4-aminophenyl)urea **267429-44-7P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(3-nitrophenyl)urea **267429-45-8P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(3-nitrophenyl)urea **267429-46-9P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(3-nitrophenyl)urea **267429-48-1P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(3-aminophenyl)urea **267429-49-2P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(3-aminophenyl)urea **267429-50-5P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(3-aminophenyl)urea **267429-51-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-benzylurea **267429-52-7P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-benzylurea **267429-53-8P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-benzylurea **267429-54-9P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-benzylurea **267429-55-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(pyrid-3-yl)urea **267429-56-1P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(pyrid-3-yl)urea **267429-57-2P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(pyrid-3-yl)urea **267429-58-3P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(pyrid-3-yl)urea

267429-59-4P, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(pyrid-4-yl)urea
267429-60-7P, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(pyrid-4-yl)urea
267429-61-8P, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(pyrid-4-yl)urea
267429-62-9P, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(pyrid-4-yl)urea **267429-63-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(pyrid-2-yl)urea **267429-64-1P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(pyrid-2-yl)urea **267429-65-2P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(pyrid-2-yl)urea **267429-66-3P**, N-(5-Cyclopropyl-1,3-thiazol-2-yl)-N'-(pyrid-2-yl)urea **267429-67-4P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(benzothiophen-2-yl)urea **267429-68-5P**, N-(5-Bromo-1,3-thiazol-2-yl)-N'-(benzothiophen-2-yl)urea **267429-69-6P**, N-(5-Phenyl-1,3-thiazol-2-yl)-N'-(benzothiophen-2-yl)urea **267429-70-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-4-morpholinecarboxamide **267429-71-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-methylphenyl)urea **267429-72-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-fluorophenyl)urea **267429-73-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-cyanophenyl)urea **267429-74-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-cyanophenyl)urea **267429-75-4P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,6-dimethylphenyl)urea **267429-76-5P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-fluorobenzyl)urea **267429-77-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-acetylphenyl)urea **267429-78-7P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-acetylphenyl)urea **267429-79-8P**, 3-[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]benzoic acid **267429-80-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-isopropylphenyl)urea **267429-81-2P**, 3-[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]benzamide **267429-82-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-methoxybenzyl)urea **267429-83-4P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-butylphenyl)urea **267429-84-5P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-[4-(trifluoromethyl)phenyl]urea **267429-85-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-bromophenyl)urea **267429-86-7P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-cyclohexylphenyl)urea **267429-87-8P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-phenoxyphenyl)urea **267429-88-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-benzyloxyphenyl)urea **267429-89-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3,5-dimethylphenyl)urea **267429-90-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3,4-dimethylphenyl)urea **267429-91-4P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-methoxy-[1,1'-biphenyl]-4-yl)urea **267429-92-5P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-3,4-dihydro-2(1H)-isoquinolinecarboxamide **267429-93-6P**, N-Benzyl-N'-(5-isopropyl-1,3-thiazol-2-yl)-N-methylurea **267429-94-7P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinecarboxamide **267429-95-8P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-chloro-4-methylphenyl)urea **267429-96-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-chloro-6-methylphenyl)urea **267429-97-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,5-dimethoxyphenyl)urea **267429-98-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3,4-dimethoxyphenyl)urea **267429-99-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-methoxy-5-chlorophenyl)urea **267430-00-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-chloro-4-methoxyphenyl)urea **267430-01-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3,5-dichlorophenyl)urea **267430-02-4P**, N-([1,1'-Biphenyl]-2-yl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-03-5P**, N-Ethyl-N'-(5-isopropyl-1,3-thiazol-2-yl)-N-phenylurea **267430-04-6P**, N-[4-[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]-2-methoxyphenyl]acetamide **267430-05-7P**, 2-[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]-N-phenylbenzamide **267430-06-8P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-morpholinophenyl)urea **267430-07-9P**, N-[4-[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]phenyl]-N-methylacetamide **267430-08-0P**, N-[2-[[Cyclohexyl(methyl)amino]methyl]phenyl]-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-09-1P**, N-[3-[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]-4-methoxyphenyl]acetamide **267430-10-4P**, N-(5-Isopropyl-1,3-thiazol-

2-yl)-4-(4-methoxyphenyl)-1-piperazinecarboxamide **267430-11-5P**, N-(2-Furylmethyl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-12-6P**, N-(4-Fluorophenyl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-13-7P**, N-(2-Methoxybenzyl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-14-8P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]urea **267430-15-9P**, N-(3,4-Dimethoxybenzyl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-16-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxamide **267430-17-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane-8-carboxamide **267430-18-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-[2-(1-piperidinyl)ethyl]urea **267430-19-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-[2-(4-morpholinyl)ethyl]urea **267430-20-6P**, 4-(4-Fluorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-1-piperazinecarboxamide **267430-21-7P**, N-[4-(4-Chlorophenyl)-3-ethyl-5-isoxazolyl]-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-22-8P**, 4-[(4-Fluorophenyl)hydroxymethyl]-N-(5-isopropyl-1,3-thiazol-2-yl)-1-piperidinecarboxamide **267430-23-9P**, N-(3-Ethynylphenyl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-24-0P**, N-(2-Methoxy-3-fluorophenyl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-25-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-oxo-1-piperidinyl)urea **267430-26-2P**, N-(3-Acetylaminophenyl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-28-4P**, N-[4-[Ethyl(isopropyl)amino]phenyl]-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-29-5P**, N-(1,3-Benzodioxol-5-yl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-30-8P**, 5-[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]-1-phenyl-1H-pyrazole-4-carboxamide **267430-31-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-pyridinylmethyl)urea **267430-32-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-pyrazinyl)urea **267430-33-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(5-phenyl-1,3,4-oxadiazol-2-yl)urea **267430-34-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinecarboxamide **267430-35-3P**, N-(1,3-Benzothiazol-6-yl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-36-4P**, N-(1,3-Dimethyl-1H-pyrazol-5-yl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-37-5P**, N-(3-Phenyl-1-methyl-1H-pyrazol-5-yl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-38-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-3-hydroxy-1-piperidinecarboxamide **267430-39-7P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)urea **267430-40-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-4-benzyl-1-piperazinecarboxamide **267430-41-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-4-methyl-1-piperazinecarboxamide **267430-42-2P**, 4-Hydroxy-N-(5-isopropyl-1,3-thiazol-2-yl)-1-piperidinecarboxamide **267430-43-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-3-azabicyclo[3.2.2]nonane-3-carboxamide **267430-44-4P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-4-(4-acetylphenyl)-1-piperazinecarboxamide **267430-45-5P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carboxamide **267430-46-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)urea **267430-47-7P**, N-(4-Phenyl-2-thiazolyl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-48-8P**, 4-(4-Fluorobenzoyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-1-piperidinecarboxamide **267430-49-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,3-dihydro-2-benzofuran-5-yl)urea **267430-50-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-4-(2-pyrimidinyl)-1-piperazinecarboxamide **267430-51-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(1H-indazol-6-yl)urea **267430-52-4P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-chlorobenzyl)urea **267430-53-5P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,4-dichlorobenzyl)urea **267430-54-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-fluorobenzyl)urea **267430-55-7P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3,4-dichlorobenzyl)urea **267430-56-8P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,4-difluorobenzyl)urea **267430-57-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,5-difluorobenzyl)urea **267430-58-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,6-difluorobenzyl)urea **267430-59-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-hydroxy-3-

methoxybenzyl)urea **267430-60-4P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(5-methyl-2-furyl)urea **267430-61-5P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-methylsulfonylbenzyl)urea **267430-62-6P**, N-[(1R,2R)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl]-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267430-63-7P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-chlorobenzyl)urea **267430-64-8P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-pyridinylmethyl)urea **267430-65-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3,5-dimethoxybenzyl)urea **267430-66-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-pyridinylmethyl)urea **267430-67-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-trifluoromethylbenzyl)urea **267430-68-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3,4,5-trimethoxybenzyl)urea **267430-69-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,4-dimethoxybenzyl)urea **267430-70-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(4-dimethylaminobenzyl)urea **267430-71-7P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,5-dimethoxybenzyl)urea **267430-72-8P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-chloro-6-phenoxybenzyl)urea **267430-73-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]urea **267430-74-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-hydroxy-4-methylphenyl)urea **267430-75-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-[4-(1H-benzimidazol-2-yl)phenyl]urea **267430-77-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-methyl-6-quinolinyl)urea **267430-78-4P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-[4-(cyanomethyl)phenyl]urea **267430-79-5P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-quinolinyl)urea **267430-80-8P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(1-oxo-2,3-dihydro-1H-inden-5-yl)urea **267430-81-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3-oxo-1,3-dihydro-2-benzofuran-5-yl)urea **267430-82-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(5-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)urea **267430-83-1P**, Methyl 3-[[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]-4-methylbenzoate **267430-84-2P**, Methyl 4-[[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]-3-methylbenzoate **267430-85-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-[4-(imidazo[1,2-a]pyridin-2-yl)phenyl]urea **267430-86-4P**, Ethyl 4-[[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]benzoate **267430-87-5P**, (2R)-N-Benzyl-2-[[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]propanamide **267430-88-6P**, 2-Hydroxy-5-[[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]benzoic acid **267430-89-7P**, 2-Chloro-5-[[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]benzoic acid **267430-90-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(5-methyl-3-isoxazolyl)urea **267430-91-1P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,6-dimethoxyphenyl)urea **267430-92-2P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,3-dimethoxybenzyl)urea **267430-93-3P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(3,4-difluorobenzyl)urea **267430-94-4P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2,4-dimethylphenyl)urea **267430-95-5P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(1H-benzimidazol-5-yl)urea **267430-96-6P** **267430-97-7P** **267430-98-8P** **267430-99-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-[3-[(1-methyl-1H-imidazol-2-yl)methoxy]phenyl]urea **267431-01-6P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-[3-(3-methoxy-1-propynyl)phenyl]urea **267431-02-7P**, N-[3-[3-(Dimethylamino)-1-propynyl]phenyl]-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267431-03-8P**, N-[4-[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]phenyl]methanesulfonamide **267431-04-9P**, 2-[3-[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]anilino]acetamide **267431-05-0P**, N-[3-(3-Hydroxy-1-butynyl)phenyl]-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267431-06-1P**, N-[(Imidazo[1,2-a]pyridin-2-yl)methyl]-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267431-07-2P**, 4-[[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl](2-propynyl)amino]methyl]benzenesulfonamide **267431-08-3P**, N-(1H-Indol-6-yl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267431-09-4P**, N-[(1S)-2-Hydroxy-1-phenylethyl]-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267431-10-7P**,

N-(1H-Indol-5-yl)-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267431-11-8P**, N-[(1R)-2-Hydroxy-1-phenylethyl]-N'-(5-isopropyl-1,3-thiazol-2-yl)urea **267431-12-9P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-butylurea **267431-13-0P**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-benzoylurea **267431-14-1P**, N-(5-Methyl-1,3-thiazol-2-yl)-N'-(2,6-dimethylphenyl)urea **267431-15-2P**, N-(5-Methyl-1,3-thiazol-2-yl)-N'-benzylurea **267431-16-3P**, N-(5-Methyl-1,3-thiazol-2-yl)-N'-butylurea **267431-17-4P**, N-(5-Methyl-1,3-thiazol-2-yl)-4-morpholinecarboxamide **267431-18-5P**, N-(5-Methyl-1,3-thiazol-2-yl)-N'-(4-methoxybenzyl)urea **267431-19-6P**, N-(5-Methyl-1,3-thiazol-2-yl)-N'-(4-fluorophenyl)urea **267431-20-9P**, N-[(1-Ethyl-2-pyrrolidinyl)methyl]-N'-(5-methyl-1,3-thiazol-2-yl)urea **267431-21-0P**, N-(5-Methyl-1,3-thiazol-2-yl)-N'-(5-hydroxy-1H-pyrazol-3-yl)urea **267431-22-1P**, N-(5-Methyl-1,3-thiazol-2-yl)-N'-(3-pyridinyl)urea **267431-27-6P**, N-[3-[[[(5-Isopropyl-1,3-thiazol-2-yl)amino]carbonyl]amino]phenyl]methanesulfonamide **267432-17-7P** **267432-18-8P**
PL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of ureidothiazole derivs. as **antitumor** agents)

IT **267431-26-5**, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(2-nitrophenyl)urea
PL: RCT (Reactant)
(starting material; prepn. of ureidothiazole derivs. as **antitumor** agents)

RN 267431-26-5 HCAPLUS
CN Urea, N-[5-(1-methylethyl)-2-thiazolyl]-N'-(2-nitrophenyl)- (9CI) (CA INDEX NAME)



i-Pr

RE.CNT 16
RE
(3) Ciba Aktiengesellschaft; CH 451156 A HCAPLUS
(4) Hoe, H; ARZNEIMITTEL FORSCHUNG DRUG RESEARCH 1987, V37(3), P306 HCAPLUS
(5) Hofmann, J; EP 0928790 A 1999 HCAPLUS
(6) Ici Ltd; FR 2302808 A 1975 HCAPLUS
(8) May & Baker Ltd; DE 2040530 A 1971 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:811221 HCAPLUS
DN 132:46695
TI Preparation of carbon substituted aminothiazole inhibitors of **cyclin** dependent kinases
IN Rawlins, David B.; Kimball, S. David; Misra, Raj N.; Kim, Kyoung S.; Webster, Kevin R.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9965884	A1	19991223	WO 1999-US13034	19990611 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9944311 A1 20000105 AU 1999-44311 19990611 <--
EP 1087951 A1 20010404 EP 1999-927401 19990611 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRAI US 1998-89747 P 19980618 <--
WO 1999-US13034 W 19990611
OS MARPAT 132:35695
GI



AB The title compds. [I; R1 = R2, COR3, CONH2, etc.; R2 = alkyl, cycloalkyl, heterocycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; A = (CR7R8)m(CR5R6)nR4 (wherein n = 0-2; m = 1-2 but both n and m cannot be 2), (CR7R8)jY(CR5R6)iR4 (i, j = 0-1 but cannot both be 1; Y = (un)substituted alkene, alkyne, any 2 adjacent carbon atoms of a cycloalkyl or cycloheteroalkyl ring of 3-7 atoms); R4 = alkyl, cycloalkyl, heterocycloalkyl, etc.; R5-R8 = H, alkyl, cycloalkyl, etc.], protein kinase inhibitors (no data) which are useful in the treatment of **proliferative** diseases, for example, **cancer**, inflammation, and arthritis, and also in the treatment of Alzheimer's disease, and cardiovascular disease, were prepd. E.g., a multi-step synthesis of (E)-II, starting with 2-aminothiazol-5-ylcarboxaldehyde, was given.

IT **252660-60-9P 252660-61-0P 252660-82-5P**
252661-05-5P 252661-06-6P 252661-07-7P
252661-08-8P 252661-09-9P 252661-10-2P
252661-11-3P 252661-12-4P 252661-13-5P
252661-14-6P 252661-15-7P 252661-16-8P
252661-17-9P 252661-18-0P 252661-19-1P
252661-20-4P 252661-21-5P 252661-22-6P
252661-23-7P 252661-24-8P 252661-25-9P
252661-26-0P 252661-27-1P 252661-28-2P
252661-29-3P 252661-31-7P 252661-32-8P
252661-33-9P 252661-35-1P 252661-36-2P
252661-37-3P 252661-38-4P 252661-39-5P
252661-40-8P 252661-41-9P 252661-42-0P
252661-43-1P 252661-44-2P 252661-45-3P
252661-46-4P 252661-48-6P 252661-49-7P
252661-54-4P 252661-55-5P 252661-56-6P
252661-62-4P 252661-63-5P 252661-69-1P
252661-70-4P 252661-71-5P 252661-97-5P
252662-14-9P 252662-16-1P
PL: BAC (Biological activity or effector, except adverse); SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of carbon substituted aminothiazole inhibitors of cyclin dependent kinases)

IT **252660-60-9P**
PL: BAC (Biological activity or effector, except adverse); SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)
(prepn. of carbon substituted aminothiazole inhibitors of cyclin dependent kinases)
RN 252660-60-9 HCAPLUS
CN Urea, N-(2,6-difluorophenyl)-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



t-Bu

RE.CNT 1
RE
(1) Boberg; US 4782162 A 1988 HCAPLUS

L26 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:776672 HCAPLUS
DN 130:38284
TI Preparation of urea derivatives as **raf** kinase inhibitors
IN Wood, Jill E.; Wild, Hanne; Rogers, Daniel H.; Lyons, John; Katz, Michael E.; Caringal, Yolanda V.; Dally, Robert; Lee, Wendy; Smith, Roger A.; Blum, Cheri L.
PA Bayer Corp., USA; Onyx Pharmaceuticals; et al.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9852559	A1	19981126	WO 1998-US10376	19980521 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9875855	A1	19981211	AU 1998-75855	19980521 <--
	EP 986382	A1	20000322	EP 1998-923601	19980521 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1997-863023		19970523 <--		
	WO 1998-US10376		19980521 <--		

AB Substituted urea compds., useful for treating **tumors** mediated by raf kinase (no data), were prepd. E.g., reaction of Me thioglycolate and 3-chloro-4-methyl-2-pentenenitrile gave 16% of the 3-aminothiophene deriv., which was reacted with 4-MeC6H4NCO to give Me 5-isopropyl-3-(3-p-tolylureido)thiophene-2-carboxylate.
IT **216589-90-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of urea derivs. as raf kinase inhibitors)

IT **216589-90-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of urea derivs. as raf kinase inhibitors)

RN 216589-90-1 HCAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1,1-dimethylethyl)-3-[[[(5-methyl-2-thiazolyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 3
RE
(1) Freed; US 5597719 A 1997 HCAPLUS
(2) Kleemann; EP 676395 A2 1996 HCAPLUS
(3) Sugen Inc; WO 96/40673 A1 1996, V87 HCAPLUS

L26 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:717901 HCAPLUS
DN 128:3680
TI Preparation of arylureas and related compounds as inhibitors of **inosine** 5'-monophosphate dehydrogenase.
IN Armistead, David M.; Badia, Michael C.; Bemis, Guy W.; Bethiel, Randy S.; Franz, Catharine A.; Novak, Perry M.; Ronkin, Steven M.; Saunders, Jeffrey O.
PA Vertex Pharmaceuticals Inc., USA
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9740028	A1	19971030	WO 1997-US6623	19970421 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5977876	A	19980915	US 1996-636361	19960423 <--
	US 6054472	A	20000425	US 1997-832165	19970402 <--
	AU 9726785	A1	19971112	AU 1997-26785	19970421 <--
	AU 723730	B2	20000907		
	EP 901782	A1	19990324	EP 1997-918759	19970421 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9708735	A	19990803	BR 1997-8735	19970421 <--
	NO 9804917	A	19981223	NO 1998-4917	19981022 <--
PRAI	US 1996-636361	A	19960423	<--	
	US 1997-801789	A	19970214	<--	
	US 1997-832165	A	19970402	<--	
	WO 1997-US6623	W	19970421	<--	

OS MARPAT 123:3680
AB ANHDNHB [A = (substituted) alkyl, alkenyl, alkynyl; B = (unsatd.) (substituted) mono- or bicyclic ring contg. 1to4req.4 heteroatoms; D = CO, CS, SO2], were prepd. Thus, 4-(5-oxazolyl)aniline and PhCH2NCO were stirred overnight in CH2Cl2 to give N-benzyl-N'-[4-(5-oxazolyl)phenyl]urea. Several title compds. inhibited IMPDH with Ki = 0.01-50 nM.
IT **198820-15-4**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of arylreas and related compds. as inhibitors of IMP dehydrogenase)
IT **198820-15-4**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of arylreas and related compds. as inhibitors of IMP dehydrogenase)
RN 198820-15-4 HCAPLUS
CN Urea, N-(5-methyl-2-thiazolyl)-N'-[4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)



L26 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2001 ACS
AN 1977:50494 HCAPLUS
DN 86:50494
TI Inhibition of solid **tumors** by nitrosoureas. 1. **Lewis lung carcinoma**
AU Montgomery, John A.; McCaleb, George S.; Johnston, Thomas P.; Mayo, Joseph G.; Laster, W. Russell, Jr.
CS Kettering-Meyer Lab., South. Res. Inst., Birmingham, Ala., USA
SO J. Med. Chem. (**1977**), 20(2), 291-5
CODEN: JMCMAR
DT Journal
LA English
AB The utility of the Lewis lung **carcinoma** as a secondary screen for the evaluation of nitrosoureas as **anticancer** agents was assessed. The activity of this series of compds. was detd. against both the early (before **metastasis**) and late (after **metastasis**) forms of the disease. Although some exceptions were noted, compds. most active against the early form of the disease were most active against the established **tumor**. A differentiation in activity based on the Lewis lung system was evident with nitrosoureas equally active against leukemia L1210, although the significance of this differentiation with respect to the human disease has not yet been established.
IT **33024-33-8**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(**neoplasm** inhibiting activity of)
IT **33024-33-8**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(**neoplasm** inhibiting activity of)
RN 33024-33-8 HCAPLUS
CN Urea, N-(2-chloroethyl)-N-nitroso-N'-(5-nitro-2-thiazolyl)- (9CI) (CA INDEX NAME)



L26 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2001 ACS
AN 1973:526436 HCAPLUS
DN 79:126436
TI Pharmaceutical 2-amino-4-aryl-5-thiazolecarboxylic acid derivatives
IN Manghisi, Elso; Salimbeni, Aldo; Fregnan, Giancarlo
PA Istituto Luso Farmaco d'Italia S.r.l.
SO Ger. Offen., 29 pp.
CODEN: GWXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2309251	A1	19730906	DE 1973-2309251	19730224 <--
	ZA 7301208	A	19740327	ZA 1973-1208	19730220 <--
	AU 7352467	A1	19740822	AU 1973-52467	19730222 <--
	BE 795807	A1	19730618	BE 1973-128061	19730223 <--
	NL 7302528	A	19730828	NL 1973-2528	19730223 <--
	US 3933838	A	19760120	US 1973-335255	19730223 <--
	ES 412052	A1	19760501	ES 1973-412052	19730224 <--
	FR 2281764	A1	19751207	FR 1973-6736	19730226 <--
	JP 48097868	A2	19731213	JP 1973-22273	19730226 <--
	JP 51012620	B4	19760421		
	GB 1425505	A	19760218	GB 1973-9382	19730226 <--
	CA 1006525	A1	19770308	CA 1973-164590	19730226 <--
PRAI	IT 1972-31086		19720225 <--		
	IT 1973-20231		19730209 <--		
	IT 1973-20231		19730209 <--		

GI For diagram(s), see printed CA Issue.
AB Nineteen thiazoles (I; n = 1 or 2; R = H, Cl, F, or OMe; R1 = H or Et; R2 = H, Et, Ac, CONHPh, Ph, or 2,6-Cl2C6H3; R3 = OH, OEt, or NHCH2CH2NEt2) were prepd. from 4-RC6H4COCHBr(CH2)nCOR3 by reaction with H2NCSNR1R2 or by reaction with H2NC(S)OEt and subsequent chlorination and reaction with R1R2NH, from I (R3 = OEt) by sapon. or reaction with Et2NCH2CH2NH2, or from I (R1 = R2 = H) by acetylation or reaction with PhNCO. Six I had antiinflammatory, antipyretic, antitussive, analgesic, and **antitumor** activity in animals and LD50 43 to >1000 and 238 to >5000 mg/kg i.p. and orally in mice, resp.
IT **49780-01-0P 49780-06-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT **49780-01-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 49780-01-0 HCAPLUS
CN 5-Thiazoleacetic acid, 4-(4-chlorophenyl)-2-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



L26 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2001 ACS
AN 1971:476218 HCAPLUS
DN 75:76218
TI Synthesis of potential **anticancer** agents. 38. N-nitrosoureas. 4. Further synthesis and evaluation of haloethyl derivatives
AU Johnston, Thomas P.; McCaler, George S.; Opliger, Pamela S.; Laster, W. Russell; Montgomery, John A.
CS Kettering-Meyer Lab., South. Res. Inst., Birmingham, Ala., USA
SO J. Med. Chem. (**1971**), 14(7), 600-14
CODEN: JMCMAR
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB N-(2-Haloethyl)-N-nitrosoureas (I), prepd. by nitrosation of the corresponding 2-haloethylureas, were tested for **anticancer** activity against both i.p. and intracerebrally inoculated marine leukemia L1210. The chemotherapeutic indices, ED50/LD10 and ED99/LD10, were compared with those of 1,3-bis(2-chloroethyl)-1-nitrosourea (II) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (III). 1-(2-Fluoroethyl)-1-nitroso-3-(tetrahydro-2H-thiopyran-4-yl) urea S,S-dioxide, 1-(2-fluoroethyl)-1-nitroso-3-(tetrahydro-2H-thiopyran-4-yl)urea and 3-(4-acetoxycyclohexyl)-1-(2-chloroethyl)-1-nitrosourea were equipotent as the ref. compds.
IT **3311-98-6P 33024-33-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT **3311-98-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 3311-98-6 HCAPLUS
CN Urea, N-(2-chloroethyl)-N'-(5-nitro-2-thiazolyl)- (9CI) (CA INDEX NAME)



=> sel hit rn 126
E1 THROUGH E297 ASSIGNED

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:27:08 ON 10 JUL 2001
USE IS SUBJECT TO THE TEPMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 9 JUL 2001 HIGHEST RN 345196-14-7
DICTIONARY FILE UPDATES: 9 JUL 2001 HIGHEST RN 345196-14-7

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.